Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic
drugs that have shown improvement in renal and cardiovascular outcomes in patients with …

Background Diabetes confers an increased risk of adverse cardiovascular and renal events.
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …

Aims/hypothesis In previous work, we reported the HR for the risk (95% CI) of the secondary
kidney composite endpoint (time to first event of doubling of serum creatinine from baseline …

An absolute, supraphysiologic elevation in GFR is observed early in the natural history in
10%–67% and 6%–73% of patients with type 1 and type 2 diabetes, respectively. Moreover …

Inhibition of the sodium–glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney
has a broad range of effects on renal function and plasma volume homeostasis, as well as …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

Background Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and
renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2
diabetes. This is possibly explained by the fact that SGLT2i normalize the measured …